OPT Opthea Ltd. Earnings per share for the last twelve months

Corporate emblem and logo of opthea.com (OPT)

Massive demand for macular degeneration therapy is being constrained by uncertainty surrounding final drug trials, creating risks for capitalization. The TTM EPS dynamics for Opthea Limited (OPT) are recorded at -2.33 on this GURU.Markets platform chart. Business stability is ensured by competent Australian management, which demonstrates full research transparency and an ability to attract global partners in ophthalmology.

OPT Opthea Limited Net earnings per one share for the last twelve months (07/04/2022 - 06/28/2025)

Opthea Ltd (OPT) - metric breakdowns and financial figures

- stock price and consensus target price:
Stock Price Opthea Limited|OPT - Average Forecast Price
- market capitalization data:
Market Value Opthea Limited|OPT - Company Buyout Price
- shareholders' equity book value data:
Net Assets per Single Share Opthea|OPT - Total Stockholders' Equity|Market Value to Book Value Ratio opthea.com|OPT - Total Asset Value of Company
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Opthea Limited|OPT - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Opthea Ltd.|OPT - Aggregate Debt Obligations|Debts to Book Capitalization Opthea Limited|OPT - Long-Term Debt|Company Short-Term Debts Opthea|Quick Liquidity Indicator opthea.com
- earnings and multiples data:
OPT - Final Profit|Expected Profit Opthea Limited|OPT - Price to Earnings Ratio|Forward P/E Multiple Opthea|OPT - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Opthea Limited|OPT - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Opthea|OPT - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months opthea.com|OPT - Net earnings per one share growth for the current year|Earnings growth forecast for next year Opthea Limited
General company analysis:Opthea Limited (OPT)
Flagship merchandise of Opthea Ltd

For Opthea Limited (OPT), EPS becomes a key indicator of capitalization efficiency amid fierce competition with ophthalmology giants. This metric is calculated by dividing the total annual net income by the total number of shares. By analyzing the EPS trend over the last 12 months, an investor assesses the real return on each share of ownership. This price action reflects the company's ability to generate profit despite pressure from blockbuster competitors. Steady growth confirms the viability of the business model.

Main competitors

Alcon Inc. - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months bausch.com|Glaukos (GKOS) - Earnings per share for the last twelve months|APLS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Belite Bio, Inc|Net earnings per one share for the last twelve months Ocular Pharma OCUL|Earnings per share for the last twelve months Harrow, Inc. (HROW)|VRDN: Earnings per one share for the last 12 months|LENZ Therapeutics - Net earnings per share for the last 12 months|Earnings per share for the last four quarters OCS (Oculis AG)|EyePoint Pharma - Net earnings per share (EPS TTM)|Earnings per share for the trailing year KOD (Kodiak Corp)|ALDX: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months KALA BIO (KALA)|IRD (Opus Genetics, Inc.) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) OKYO Pharma Inc|Net earnings per share for the last 12 months ADVM (Adverum Biotechnologies)|OTLK (Outlook Therapeutics Corp) - Earnings per share for the trailing year|Earnings per share for the last twelve months Clearside Biomedical CLSD|NovaBay Pharmaceuticals Inc. - Earnings per share for the last twelve months|Kiora Pharma - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Alimera Sciences ALIM|eyenovia.com (EYEN) - Earnings per share for the last twelve months|Net earnings per share for the last 12 months Guardion Health|OCUP (Ocuphire Pharma, Inc.) - Net earnings per share (EPS TTM)